

This promotional poster has been developed by MSD for UK Healthcare Professionals.

HELP PROTECT AGAINST THE RISK OF PNEUMOCOCCAL DISEASE WITH PPV23, AS PART OF THE NATIONAL IMMUNISATION PROGRAMME

Prescribing Information for the UK can be found at www.emcpi.com/pi/35695.

PNEUMOVAXTM23
(Pneumococcal Polysaccharide Vaccine)

Who is eligible for PPV23 vaccine, as part of the national immunisation programme?¹



Eligible adults aged **65 years and over**



At-risk groups aged 2 years and over,^{1,2} including patients with chronic respiratory disease; diabetes mellitus requiring insulin or anti-diabetic medication and chronic heart disease*¹

*Please refer to the Green Book - Immunisation against infectious disease (Chapter 25)¹, for a full list of children aged 2 years and over and adults, considered at-risk.

Why should vaccination against pneumonia be one of your priorities?

19,500+
DEATHS PER ANNUM¹

Pneumonia is associated with **high UK mortality** rates³



Over 65-year-olds and at-risk individuals all have a **high risk** of morbidity and mortality from pneumonia⁴⁻⁷



However, pneumonia often isn't **top of mind** for a healthy over 65-year-old

The specific at-risk categories of persons to be immunised are to be determined on the basis of official recommendations. Please consult the SmPC for further information before making any prescribing decisions.

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme Limited (Tel: 0208 154 8000). By clicking the above link, you will leave the MSD website and be taken to the MHRA website.

This digital poster has been produced by MSD.

PPV23 is in stock and ready to order



PPV23 is **in stock** and available to order via the ImmForm website (for GP surgeries) and Alliance (for pharmacies)



PPV23 is **coded** within EPR systems



Most of your eligible patients only need a **single dose**^{1,2}

*Revaccination may be needed in certain at-risk groups. The timing and need of revaccination should be determined on the basis of official recommendations.

Please consult the SmPC for further information before making any prescribing decisions.

ORDER AND START VACCINATING TODAY

Order from
Alliance
Pharmacies →

Order from the
Immform Website
GP Surgeries →

These links will direct you to third-party websites[§]

PNEUMOVAX[®] 23 (pneumococcal polysaccharide vaccine) is recommended for active immunisation against pneumococcal disease in children aged from 2 years, adolescents and adults.

¹Deaths involving pneumonia in the United Kingdom 2020; total mortality per annum was 19,642.

[§]MSD makes no warranties or representations of any kind as to the accuracy, completeness, reliability or usefulness of any information contained in third party sites and shall have no liability for any loss or damage of any kind that may arise from your use of such content or information. Inclusion of any third-party link does not imply an endorsement or recommendation by MSD.

CHD, chronic heart disease; COPD, chronic obstructive pulmonary disease; EPR, electronic patient record; MHRA, Medicines and Healthcare products Regulatory Agency; NICE, National Institute for Health and Care Excellence; PPV, pneumococcal polysaccharide vaccine; SmPC, Summary of Product Characteristics.

References: 1. The Green Book - Immunisation against infectious disease (January 2020). Chapter 25 - Pneumococcal. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/857267/GB_Chapter_25_pneumococcal_January_2020.pdf [Accessed April 2023]; 2. Pneumovax-23 Summary of Product Characteristics. Available at: <https://www.medicines.org.uk/emc/product/9692/smhc>. [Accessed April 2023]; 3. Office for National Statistics. UK pneumonia deaths 2020 and 2021. Available at: <https://www.ons.gov.uk/aboutus/transparencyandgovernance/freedomofinformationfoi/ukpneumoniadeaths2020and2021> [Accessed April 2023]; 4. Martins M, et al. *BMJ Open Diabetes Res Care* 2016;4:e000181; 5. Falcone M, et al. *Medicine* 2016;95(5):e2531; 6. Restrepo MI, et al. *Tuberc Respir Dis* 2018;81:187-197; 7. Dai RX, et al. *BMC Pulm Med* 2018;18(1):12.

GB-PNX-00306 | May 2023